TP53 mutations are reported in at least 80% of advanced serous OC cases, and the poor prognosis associated with TP53 mutations is thought to be due to the resistance of cancer cells to chemotherapy-induced apoptosis (Duffy et al., 2017). The gene discussed is TP53; the disease is cancer.